|
1
|
Erickson BK, Conner MG and Landen CN Jr:
The role of the fallopian tube in the origin of ovarian cancer. Am
J Obstet Gynecol. 209:409–414. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kurman RJ and Shih IM: The origin and
pathogenesis of epithelial ovarian cancer: A proposed unifying
theory. Am J Surg Pathol. 34:433–443. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Prat J: New insights into ovarian cancer
pathology. Ann Oncol. 23 Suppl 10:x111–x117. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Eltabbakh GH and Awtrey CS: Current
treatment for ovarian cancer. Expert Opin Pharmacother. 2:109–124.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Noone AM, Howlader N, Krapcho M, Miller D,
Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, et al:
SEER Cancer Statistics Review, 1975–2015. National Cancer
Institute; Bethesda, MD: 2018, https://seer.cancer.gov/csr/1975_2015/April.
2018
|
|
6
|
Komiyama S, Katabuchi H, Mikami M, Nagase
S, Okamoto A, Ito K, Morishige K, Suzuki N, Kaneuchi M, Yaegashi N,
et al: Japan society of gynecologic oncology guidelines 2015 for
the treatment of ovarian cancer including primary peritoneal cancer
and fallopian tube cancer. Int J Clin Oncol. 21:435–446. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kigawa J: New strategy for overcoming
resistance to chemotherapy of ovarian cancer. Yonago Acta Med.
56:43–50. 2013.PubMed/NCBI
|
|
8
|
Kandalaft LE, Powell DJ Jr, Singh N and
Coukos G: Immunotherapy for ovarian cancer: What's next? J Clin
Oncol. 29:925–933. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang RF and Wang HY: Immune targets and
neoantigens for cancer immunotherapy and precision medicine. Cell
Res. 27:11–37. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Drerup JM, Liu Y, Padron AS, Murthy K,
Hurez V, Zhang B and Curiel TJ: Immunotherapy for ovarian cancer.
Curr Treat Options Oncol. 16:3172015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen L and Han X: Anti-PD-1/PD-L1 therapy
of human cancer: Past, present, and future. J Clin Invest.
125:3384–3391. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang L, Rubinstein R, Lines JL, Wasiuk A,
Ahonen C, Guo Y, Lu LF, Gondek D, Wang Y, Fava RA, et al: VISTA, a
novel mouse Ig superfamily ligand that negatively regulates T cell
responses. J Exp Med. 208:577–592. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lines JL, Sempere LF, Broughton T, Wang L
and Noelle R: VISTA is a novel broad-spectrum negative checkpoint
regulator for cancer immunotherapy. Cancer Immunol Res. 2:510–517.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lines JL, Pantazi E, Mak J, Sempere LF,
Wang L, O'Connell S, Ceeraz S, Suriawinata AA, Yan S, Ernstoff MS
and Noelle R: VISTA is an immune checkpoint molecule for human T
cells. Cancer Res. 74:1924–1932. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Deng J, Le Mercier I, Kuta A and Noelle
RJ: A New VISTA on combination therapy for negative checkpoint
regulator blockade. J Immunother Cancer. 4:862016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Okudaira K, Hokari R, Tsuzuki Y, Okada Y,
Komoto S, Watanabe C, Kurihara C, Kawaguchi A, Nagao S, Azuma M, et
al: Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a
mouse pancreatic cancer model. Int J Oncol. 35:741–749.
2009.PubMed/NCBI
|
|
17
|
Hu Q, Peng J, Liu W, He X, Cui L, Chen X,
Yang M, Liu H, Liu S and Wang H: Lin28B is a novel prognostic
marker in gastric adenocarcinoma. Int J Clin Exp Pathol.
7:5083–5092. 2014.PubMed/NCBI
|
|
18
|
Wang Q, Li J, Li G, Li Y, Xu C, Li M, Xu G
and Fu S: Prognostic significance of sphingosine kinase 2
expression in non-small cell lung cancer. Tumour Biol. 35:363–368.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Böger C, Behrens HM, Krüger S and Röcken
C: The novel negative checkpoint regulator VISTA is expressed in
gastric carcinoma and associated with PD-L1/PD-1: A future
perspective for a combined gastric cancer therapy? Oncoimmunology.
6:e12932152017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu L, Deng WW, Huang CF, Bu LL, Yu GT, Mao
L, Zhang WF, Liu B and Sun ZJ: Expression of VISTA correlated with
immunosuppression and synergized with CD8 to predict survival in
human oral squamous cell carcinoma. Cancer Immunol Immunother.
66:627–636. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ni L and Dong C: New checkpoints in cancer
immunotherapy. Immunol Rev. 276:52–65. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Le Mercier I, Chen W, Lines JL, Day M, Li
J, Sergent P, Noelle RJ and Wang L: VISTA regulates the development
of protective antitumor immunity. Cancer Res. 74:1933–1944. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nicklin JL, McGrath S, Tripcony L, Garrett
A, Land R, Tang A, Perrin L, Chetty N, Jagasia N, Crandon AJ, et
al: The shift toward neo-adjuvant chemotherapy and interval
debulking surgery for management of advanced ovarian and related
cancers in a population-based setting: Impact on clinical outcomes.
Aust N Z J Obstet Gynaecol. 57:651–658. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hu Q, Peng J, Liu W, He X, Cui L, Chen X,
Yang M, Liu H, Liu S and Wang H: Elevated cleaved caspase-3 is
associated with shortened overall survival in several cancer types.
Int J Clin Exp Pathol. 7:5057–5070. 2014.PubMed/NCBI
|
|
26
|
Webb JR, Milne K, Kroeger DR and Nelson
BH: PD-L1 expression is associated with tumor-infiltrating T cells
and favorable prognosis in high-grade serous ovarian cancer.
Gynecol Oncol. 141:293–302. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Markman M: Immunotherapy in ovarian
cancer-where are we going? Am J Hematol Oncol. 12:2016.
|
|
28
|
Kandalaft LE, Motz GT, Duraiswamy J and
Coukos G: Tumor immune surveillance and ovarian cancer: Lessons on
immune mediated tumor rejection or tolerance. Cancer Metastasis
Rev. 30:141–151. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
De Felice F, Marchetti C, Palaia I, Musio
D, Muzii L, Tombolini V and Panici PB: Immunotherapy of ovarian
cancer: The role of checkpoint inhibitors. J Immunol Res.
2015:1918322015. View Article : Google Scholar : PubMed/NCBI
|
